EGFR and non-small cell lung carcinoma: Additionally, Osimertinib is reimbursed as a second-line therapy for EGFR-mutation-positive advanced NSCLC in cases of disease progression during Gefitinib, Erlotinib, or Afatinib treatment, provided that there is an acquired T790M mutation [20].